Collagenosis, Familial Reactive Perforating

Last update 08 May 2025

Basic Info

Synonyms

COLLAGENOSIS, FAMILIAL REACTIVE PERFORATING, Collagenosis, Familial Reactive Perforating, Familial reactive perforating collagenosis

+ [2]

Introduction

Familial reactive perforating collagenosis is a very rare genetic skin disease characterized by transepidermal elimination of collagen fibers presenting as recurrent spontaneously involuting keratotic papules or nodules.

Clinical Trials associated with Collagenosis, Familial Reactive Perforating

JPRN-jRCT2021230034

/ SuspendedPhase 2IIT

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Nemolizumab in Patients with Acquired Reactive Perforating Collagenosis

Start Date09 Nov 2023

Sponsor / Collaborator-

100 Clinical Results associated with Collagenosis, Familial Reactive Perforating

100 Translational Medicine associated with Collagenosis, Familial Reactive Perforating

0 Patents (Medical) associated with Collagenosis, Familial Reactive Perforating

445

Literatures (Medical) associated with Collagenosis, Familial Reactive Perforating

01 Dec 2025·Techniques in Coloproctology

Feasibility and usefulness of the elongation of ileocolic pedicle with extended ileal resection on secure anastomosis after laparoscopic restorative proctocolectomy: a retrospective observational study

Article

Author: Nakamura, Masafumi ; Okuyama, Keiichiro ; Mizuuchi, Yusuke ; Noshiro, Hirokazu ; Fujimoto, Takaaki ; Tanaka, Futoshi ; Manabe, Tatsuya ; Takesue, Shin

PURPOSETension-free ileal pouch-anal anastomosis (IPAA) in restorative proctocolectomy (RPC) for ulcerative colitis (UC) and familial adenomatous polyposis (FAP) is important for avoiding anastomotic complications. We have employed the elongation of ileocolic pedicle (ICP) with extended ileal resection as one of the mesenteric-lengthening techniques. In this study, we examined the feasibility and usefulness of our mesenteric-lengthening technique.METHODSThis retrospective study enrolled 60 patients for whom laparoscopic RPC with IPAA was electively planned for UC and FAP from January 2009 to December 2022. In 41 patients ("conventional group"), the ileum was cut flush to the cecum without ileal resection, and in 19 patients ("experimental group"), the elongation of the ICP with extended ileal resection was conducted. The short-term outcomes were compared between the two groups, and the risk factor for anastomotic complications was examined.RESULTSThe preoperative and intraoperative parameters did not differ between the two groups. However, the incidence of anastomosis-related complications (ARCs) was significantly lower in the experimental group than in the conventional group (0.0% versus 14.6%, respectively; p = 0.027). Univariate analysis demonstrated that the elongation of the ICP with extended ileal resection was significantly correlated with ARCs (p = 0.027 and p = 0.030, respectively), although multivariate analysis did not show the independent factors.CONCLUSIONThe lengthening technique using the elongation of the ICP with extended ileal resection is feasible and safe, and might be one choice for secure IPAA during the laparoscopic approach for RPC.

01 May 2025·Annals of Oncology

The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study

Article

Author: Giani, A ; Sutcliffe, R ; Goodsell, K E ; Sánchez-Velázquez, P ; Amaral, M J ; Takeyama, Y ; Ferrari, G ; Satoi, S ; Sparrelid, E ; van Bodegraven, E A ; Socratous, A ; Matsumoto, I ; Luyer, M D ; Hirano, S ; Yamaki, S ; Uemura, K ; Padbury, R ; Hogg, M E ; de Franco, L ; Kazemier, G ; Abu Hilal, M ; Nagakawa, Y ; Hüttner, F J ; Motoi, F ; Rojas, A ; Kauffman, E F ; Davide, J ; Flanking, D ; Sauvanet, A ; D'Hondt, M ; Serrablo, A ; Rodriguez Franco, S ; Oba, A ; Mora-Oliver, I ; Månsson, C ; Murakami, T ; Soonawalla, Z ; Björnsson, B ; Del Chiaro, M ; Okano, K ; Patel, B Y ; Brunner, M ; Patel, R B ; Labori, K J ; Sham, J G ; Rangelova, E ; Tingstedt, B ; Sumiyoshi, T ; Wolfgang, C L ; Takami, H ; Zerbi, A ; Gramellini, M ; Cabús, S S ; Burdio, F ; Holka, P S ; Berrevoet, F ; Butturini, G ; van Dam, M A ; Jamieson, N B ; Schulick, R D ; Karteszi, H ; van Laarhoven, S ; Kawamoto, Y ; Kilburn, D ; Messersmith, W ; Fabre, J M ; Bilge, O ; Javed, A A ; Busch, O R ; Kirkov, L ; Pando, E ; Koh, Y X ; Grützmann, R ; Wijma, A G ; Hashimoto, D ; Imamura, M ; Zironda, A ; Suto, H ; Giannone, F ; Douchi, D ; Janot, M ; Kito Fusai, G ; Unno, M ; Ghorbani, P ; Maithel, S K ; Chen, J ; Webber, L ; Ausania, F ; Mizuma, M ; Pessaux, P ; de Martino, J ; Bartholomä, W ; Kleive, D ; Cho, Y ; Halimi, A ; Nakamura, T ; Kamei, K ; Del Pozo, C D ; Alberici, L ; Jang, J Y ; van Eijck, C H J ; Arshad, A ; Frigerio, I ; Mieog, J S D ; Suárez-Muñoz, M Á ; Kozono, S ; Inoue, Y ; Sugawara, T ; Gaujoux, S ; Hayashi, M ; Maglione, M ; Thiels, C A ; Daams, F ; Takahashi, R ; Ricci, C ; Chai, S M ; Stommel, M W J ; de Ponthaud, C ; Codjia, T ; Goh, B K P ; Tanaka, K ; Souche, F R ; Sartoris, R ; Hughes, D L ; Giardino, A ; Belyaev, O ; González-Abós, C ; Silva, D S ; de Meijer, V E ; Kwon, W ; Urdzik, J ; Saliba, G ; Medin, C ; van Ramshorst, T M E ; Wilmink, J W ; Ome, Y ; Moltzer, E ; Hartman, V ; Karsten, T M ; Truty, M J ; Mata, R ; Sahakyan, M A ; Steyerberg, E ; Nappo, G ; Petrikowski, M ; Warren, E ; Jain, A ; Sergeant, G ; Franklin, O ; Takishita, C ; Verkolf, E ; Ramaekers, M ; Ejaz, A ; Bozkurt, E ; Honda, G ; Stoop, T F ; Nielsen, K ; Payá-Llorente, C ; Schwabl, C ; Coratti, A ; Roeyen, G ; Besselink, M G ; Banerjee, A ; Reames, B N ; Ali, M ; Boggi, U ; Casadei, R ; Zhang, C ; Okada, K ; Festen, S ; Edil, B H ; Thoma, E ; Miyashita, M ; Ramera, M

BACKGROUNDLeft-sided pancreatic cancer is associated with worse overall survival (OS) compared with right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with resectable pancreatic cancer (RPC), current randomized trials included mostly patients with right-sided RPC. The purpose of this study was to assess the association between neoadjuvant therapy and OS in patients with left-sided RPC compared with upfront surgery.PATIENTS AND METHODSThis was an international multicenter retrospective study including consecutive patients after left-sided pancreatic resection for pathology-proven RPC, either after neoadjuvant therapy or upfront surgery in 76 centers from 18 countries on 4 continents (2013-2019). The primary endpoint was OS from diagnosis. Time-dependent Cox regression analysis was carried out to investigate the association of neoadjuvant therapy with OS, adjusting for confounders at the time of diagnosis. Adjusted OS probabilities were calculated.RESULTSOverall, 2282 patients after left-sided pancreatic resection for RPC were included of whom 290 patients (13%) received neoadjuvant therapy. The most common neoadjuvant regimens were (m)FOLFIRINOX (38%) and gemcitabine-nab-paclitaxel (22%). After upfront surgery, 72% of patients received adjuvant chemotherapy, mostly a single-agent regimen (74%). Neoadjuvant therapy was associated with prolonged OS compared with upfront surgery (adjusted hazard ratio 0.69, 95% confidence interval 0.58-0.83) with an adjusted median OS of 53 versus 37 months (P = 0.0003) and adjusted 5-year OS rates of 47% versus 35% (P = 0.0001) compared with upfront surgery. Interaction analysis demonstrated a stronger effect of neoadjuvant therapy in patients with a larger tumor (P_interaction = 0.003) and higher serum carbohydrate antigen 19-9 (CA19-9; P_interaction = 0.005). In contrast, the effect of neoadjuvant therapy was not enhanced for splenic artery (P_interaction = 0.43), splenic vein (P_interaction = 0.30), retroperitoneal (P_interaction = 0.84), and multivisceral (P_interaction = 0.96) involvement.CONCLUSIONSNeoadjuvant therapy in patients with left-sided RPC was associated with improved OS compared with upfront surgery. The impact of neoadjuvant therapy increased with larger tumor size and higher serum CA19-9 at diagnosis. Randomized controlled trials on neoadjuvant therapy specifically in patients with left-sided RPC are needed.

01 Apr 2025·JAMA Dermatology

Tofacitinib for Treatment of Acquired Reactive Perforating Collagenosis

Article

Author: Liu, Hong ; Yuan, Ruiqing ; Zhou, Guizhi

This case report describes a woman in her 50s with type 2 diabetes who presented with multiple erythematous dome-shaped umbilicated papules and nodules with scablike central plugs on the trunk and limbs.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Collagenosis, Familial Reactive Perforating

Basic Info

Related

Analysis